1201643-80-2

Upstream product

• 10075-50-0 5-bromo-1H-indole 
• 129488-74-0 4-(1-cyano-1-methylethyl)benzoic acid 
• 98-59-9 p-toluenesulfonyl chloride 
• 96546-77-9 N-tosyl-5-bromoindole 
• 40119-34-4 2-methyl-2-(4-methylphenyl)propionitrile 
• 1201643-79-9 2-(4-((5-bromo-1-tosyl-1H-indol-3-yl)(hydroxy)methyl)phenyl)-2-methylpropanenitrile 
• 1201643-78-8 2-(4-(5-bromo-1-tosyl-1H-indol-3-carbonyl)phenyl)-2-methylpropanenitrile 

Downstream Products

• 1201643-81-3 2-(4-((5-bromo-1H-indol-3-yl)methyl)phenyl)-2-methylpropanenitrile 
• 1201645-56-8 N-(5-(1-(4-(2-cyanopropan-2-yl)phenyl)-3H-pyrazolo[3,4-c]quinolin-8-yl)pyridine-3-yl)benzenesulfonamide 
• 1201645-37-5 N-(5-(3-acetyl-1-(4-(2-cyanopropan-2-yl)phenyl)-3H-pyrazolo[3,4-c]quinolin-8-yl)pyridin-2-yl)acetamide 
• 1201645-08-0 2-methyl-2-(4-(8-(3-(4-methylpiperazin-1-yl)phenyl)-3H-pyrazolo[3,4-c]quinolin-1-yl)phenyl)propanenitrile 
• 1201645-49-9 N-(3-(1-(4-(2-cyanopropan-2-yl)phenyl)-3H-pyrazolo[3,4-c]quinolin-8-yl)phenyl)benzamide 
• 1201645-42-2 2-(4-(8-(9H-carbazol-2-yl)-3H-pyrazolo[3,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201645-75-1 2-(4-(3-acetyl-8-(4-methylsulfonylpiperazin-1-yl)-3H-pyrazolo[3,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201645-41-1 2-(4-(3-acetyl-8-(6-phenoxypyridin-3-yl)-3H-pyrazolo[3,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201644-55-4 tert-butyl 5-(1-(4-(2-cyanopropan-2-yl)phenyl)-3H-pyrazolo[3,4-c]quinolin-8-yl)pyridin-3-ylcarbamate 
• 1286756-81-7 C₃₁H₃₁N₅O₂ 
• 1201645-33-1 2-(4-(3-acetyl-8-(6-chlorothieno[2,3-b]pyridin-2-yl)-3H-pyrazolo[3,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1201645-80-8 C₂₇H₃₁N₅O₃S 
• 1286762-08-0 C₃₁H₃₃N₅ 
• 1201645-14-8 2-(4-(8-(1H-indazol-6-yl)-3H-pyrazolo[3,4-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 

Relevant academic research and scientific papers

PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS

Provided are compounds according to Formula (I), or stereoisomer, prodrug, polymorph, or pharmaceutically acceptable salt forms thereof, wherein X, Y, R1, R6 , R7, and R8 are as defined, which compounds are effective inhibitors of PI3-kinase and/or other medically and clinically relevant kinases. Also provided are pharmaceutical compositions and methods of using the compounds and compositions as PB -kinase and kinase inhibitors. More particularly, the compounds of the invention provide treatments and therapeutics for human diseases regulated by, or associated with, the activity of, PI3-kinases and/or protein kinases, or mutant or variant forms thereof.